证券代码：300725 证券简称：药石科技 公告编号：2025-098 南京药石科技股份有限公司 第四届董事会第十一次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 南京药石科技股份有限公司（以下简称"公司"）第四届董事会第十一次会 议于2025年10月29日以现场结合视频会议形式在公司会议室召开，以书面方式进 行表决。会议通知已于2025年10月26日通过电子邮件等方式送达各位董事。会议 由董事长杨民民先生召集主持，应出席董事人数7人，实际出席董事人数7人。公 司部分高级管理人员列席会议。本次会议的召集、召开符合《中华人民共和国公 司法》和《南京药石科技股份有限公司公司章程》等有关规定。 一、 董事会会议审议情况 会议在保证所有董事充分发表意见的前提下，以投票表决方式通过了以下议 案： 1、审议通过了《关于公司<2025 年第三季度报告>的议案》。 经审核，董事会认为：公司 2025 年第三季度报告的编制程序符合法律、行 政法规和中国证监会的规定，报告内容真实、准确、完整地反映了公司的实际情 况，不存在任何虚假记载、误导性陈述或者重大遗漏。 本 ...

Financial Performance - The company's revenue for Q3 2025 reached ¥499,325,806.76, representing a 30.36% increase year-over-year[6] - Net profit attributable to shareholders was ¥40,892,532.15, up 23.54% compared to the same period last year[6] - The net profit after deducting non-recurring gains and losses was ¥28,536,287.99, reflecting a 41.85% increase year-over-year[6] - The company achieved a revenue of 1.419 billion RMB in the first three quarters of 2025, representing a year-on-year growth of 25.81%[17] - Revenue from drug development and commercialization services was 1.179 billion RMB, reflecting a year-on-year increase of 34.91%[17] - Total operating revenue for the current period reached ¥1,419,054,885.82, an increase of 25.7% compared to ¥1,127,892,555.29 in the previous period[24] - The net profit for the current period is CNY 113,390,631.27, a decrease of 13.9% compared to CNY 131,790,818.60 in the previous period[25] - The total profit for the current period is CNY 128,234,163.84, down from CNY 147,998,927.07 in the previous period[25] Assets and Liabilities - Total assets as of September 30, 2025, amounted to ¥7,794,641,752.32, a 57.94% increase from the end of the previous year[6] - The company's equity attributable to shareholders increased by 139.29% to ¥7,149,000,685.97 compared to the end of the previous year[6] - Total liabilities decreased to ¥645,641,066.35 from ¥1,947,719,670.04, a decline of 66.9%[22] - Non-current assets increased to ¥5,131,662,934.01 from ¥2,218,334,497.16, reflecting a growth of 131.5%[21] Cash Flow - Cash flow from operating activities for the year-to-date reached ¥543,482,604.71, a significant increase of 187.74%[6] - The net cash flow from operating activities was 543 million RMB, a significant increase of 187.74% compared to the same period last year[18] - The cash flow from investing activities shows a net outflow of CNY 307,707,118.32, compared to a smaller outflow of CNY 5,986,725.75 in the previous period[28] - The cash flow from financing activities resulted in a net outflow of CNY 247,171,819.29, an improvement from a net outflow of CNY 377,079,879.92 in the previous period[28] Shareholder Information - The total number of common shareholders at the end of the reporting period was 46,457[12] - The largest shareholder, Yang Minmin, holds 17.71% of the shares, amounting to 41,403,319 shares, with 12 million shares pledged[12] Cost Management - The company reported a 44.13% increase in operating costs, totaling ¥979,876,477.06 for the year-to-date[10] - Total operating costs amounted to ¥1,281,579,226.63, up 26.6% from ¥1,011,642,933.42 in the prior period[24] - The company reported a net profit margin improvement, with operating costs growing at a slower rate than revenue[24] - The company plans to maintain dynamic balance between cost control and strategic development to support long-term sustainable growth[17] Market and Business Development - New orders for CDMO services increased by 15% year-on-year, with new business orders for peptides and ADCs growing by over 100%[18] - The company is focusing on expanding its market presence and enhancing product development strategies moving forward[24] - The company is prioritizing resource allocation towards technology services and CMC business to strengthen long-term partnerships with core clients[17] Other Financial Metrics - The basic earnings per share for Q3 2025 was ¥0.2032, up 22.12% year-over-year[6] - Basic earnings per share decreased to 0.5635 from 0.6626 in the previous period[26] - The company experienced a foreign exchange impact of CNY 1,465,968.39 on cash and cash equivalents[28] - The company reported a significant increase in other income to CNY 16,262,839.51 from CNY 7,184,657.22 in the previous period[25] - The total comprehensive income for the current period is CNY 3,058,673,130.81, significantly higher than CNY 130,726,069.30 in the previous period[26]

Core Viewpoint - The company emphasizes its commitment to solid operational performance and sustainable growth as the foundation for enhancing intrinsic value and providing the best returns to shareholders [1] Group 1: Company Performance and Strategy - The management is closely monitoring the company's performance in the capital market and understands investors' concerns regarding stock price trends [1] - The company is focusing on the development of its core business by continuously improving operational management, deepening technological innovation, and optimizing customer and business structure [1] - The management is dedicated to strengthening the company's fundamentals to drive continuous growth in intrinsic value [1] Group 2: Future Plans and Disclosure - The company will adhere to the regulations of the Shenzhen Stock Exchange's Growth Enterprise Market regarding any future buyback plans or related measures, ensuring timely information disclosure [1]

Core Insights - The Biotech Economy Index (970038) closed at 2261.4 points, down 0.81%, with a trading volume of 16.635 billion yuan and a turnover rate of 1.19% [1] - Among the index constituents, 19 stocks rose while 30 stocks fell, with Meihao Medical leading the gainers at 6.53% and Prolo Pharma leading the decliners at 5.41% [1] Index Performance - The Biotech Economy Index experienced a decline of 0.81% on the reporting day [1] - The total market capitalization of the index constituents was significant, with major players like Mindray Medical valued at 266.98 billion yuan [1] Top Constituents - The top ten constituents of the Biotech Economy Index include: - Mindray Medical (13.81% weight, 220.20 yuan, -1.51% change, 2669.80 billion yuan market cap) [1] - Changchun High-tech (5.41% weight, 119.11 yuan, -0.97% change, 485.89 billion yuan market cap) [1] - Kanglong Chemical (4.66% weight, 30.96 yuan, +0.29% change, 550.53 billion yuan market cap) [1] - Other notable constituents include Taige Pharmaceutical, Muyuans, and Aimeike, all within the biotech and healthcare sectors [1] Capital Flow - The net outflow of main funds from the Biotech Economy Index constituents totaled 0.893 billion yuan, while retail investors saw a net inflow of 0.75 billion yuan [1] - Specific stocks like Kanglong Chemical and Meihao Medical experienced varying levels of net inflow and outflow from different investor categories [2]

Core Insights - The second Green Chemistry Forum organized by Yaoshi Technology took place in Nanjing, focusing on the green transformation in the medical industry within global supply chain management [1][3] Group 1: Forum Highlights - The forum gathered over 100 industry experts and scholars to discuss sustainable development pathways for the pharmaceutical industry [1][3] - Key discussions revolved around new concepts, technologies, and applications in green chemistry [3] - Yaoshi Technology's CEO, Yang Minmin, emphasized the future reliance on AI technology to shorten R&D cycles and enhance precision while exploring safe, environmentally friendly, and low-carbon production methods [3] Group 2: Industry Development - Nanjing Biomedical Valley hosts over 1,300 biopharmaceutical companies and collaborates with Nanjing University and China Pharmaceutical University to establish the Nanchuang Institute of Chemistry and Life Health [3] - The initiative aims to promote the transformation of cutting-edge technologies such as synthetic biology and gene sequencing [3]

Core Viewpoint - The stock of Yaoshi Technology has experienced fluctuations, with a recent decline of 2.01% and a year-to-date increase of 18.33%, indicating volatility in its market performance [1]. Financial Performance - As of September 30, Yaoshi Technology reported a revenue of 920 million yuan for the first half of 2025, reflecting a year-on-year growth of 23.48%. However, the net profit attributable to shareholders decreased by 26.54% to 72.5 million yuan [2]. - Cumulatively, since its A-share listing, Yaoshi Technology has distributed a total of 231 million yuan in dividends, with 137 million yuan distributed over the past three years [3]. Shareholder Information - The number of shareholders for Yaoshi Technology as of September 30 is 46,500, a decrease of 2.94% from the previous period. The average number of circulating shares per person increased by 3.03% to 4,363 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 2.1466 million shares, a decrease of 1.2259 million shares from the previous period, while Southern CSI 1000 ETF increased its holdings by 278,200 shares to 1.4751 million shares [3]. Business Overview - Yaoshi Technology, established on December 26, 2006, and listed on November 10, 2017, is primarily engaged in the research, development, production, and sales of drug molecular building blocks. Its revenue composition includes 83.14% from drug development and commercialization services, 16.72% from drug research services, and 0.14% from other sources [1]. - The company operates within the pharmaceutical and biotechnology sector, specifically in medical services and medical research outsourcing, and is involved in synthetic biology, biopharmaceuticals, innovative drugs, and cancer drugs [1].

（文章来源：证券日报） 证券日报网讯药石科技10月13日在互动平台回答投资者提问时表示，截至2025年9月30日，公司股东人 数为：46457户。 ...

Core Viewpoint - The share reduction plan by Nanjing Novicos Venture Capital Partnership has been completed, resulting in a total cash inflow of 229 million yuan for the company [1]. Group 1: Share Reduction Details - Nanjing Novicos reduced 1,974,244 shares through centralized bidding at an average price of 46.21 yuan from August 11 to September 29, 2025 [2]. - Additionally, 3,430,500 shares were reduced through block trading at an average price of 40.18 yuan from August 13 to September 26, 2025 [2]. - The total shares reduced by Nanjing Novicos amounted to 5,404,744 shares [1][2]. Group 2: Shareholder Information - The controlling shareholder and actual controller of the company is Yang Minmin, who is also the executive partner of Nanjing Novicos [3]. - Nanjing Novicos is considered a concerted actor with Yang Minmin, indicating a close relationship in decision-making [3].

Core Viewpoint - The employee shareholding platform of Yaoshi Technology, Novicos, has completed its share reduction plan, selling a total of 5.404744 million shares, which accounts for 2.32% of the total share capital after excluding repurchased shares [1] Summary by Category Share Reduction Details - Novicos reduced its holdings from August 11, 2025, to September 29, 2025, through centralized bidding and block trading [1] - The centralized bidding resulted in a reduction of 1.974244 million shares at an average price of 46.21 CNY per share [1] - The block trading led to a reduction of 3.430500 million shares at an average price of 40.18 CNY per share [1] - The total estimated amount from the share reduction is approximately 229 million CNY [1] - After this reduction, Novicos no longer holds any shares in Yaoshi Technology [1]

证券代码：300725 证券简称：药石科技 公告编号：2025-096 南京药石科技股份有限公司 关于股东减持股份计划实施完成的公告 股东南京诺维科思创业投资合伙企业（有限合伙）保证向本公司提供的信息 内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 南京药石科技股份有限公司（以下简称"公司"）于2025年7月10日披露了 《关于公司股东减持股份的预披露公告》（公告编号：2025-044）。公司员工持 股平台南京诺维科思创业投资合伙企业（有限合伙）（以下简称"诺维科思"） 计划在本减持计划预披露公告之日起十五个交易日后的三个月内（窗口期不减 持），以集中竞价、大宗交易方式减持其持有的全部公司股份。其中，通过集中 竞价交易方式减持的，在任意连续90个自然日内减持股份数量不超过公司股份总 数的1.00%；通过大宗交易方式减持的，在任意连续90个自然日内减持股份数量 不超过公司股份总数的2.00%（减持期间如公司有送股、资本公积金转增股本等 导致持股数量变化，则减持数量进行相应调整）。 2025年9月29日，公司收到了诺维科思出具的《关于 ...